{"id":5409,"date":"2018-09-28T14:02:01","date_gmt":"2018-09-28T18:02:01","guid":{"rendered":"http:\/\/www.ipoboutique.com\/blog\/?p=5409"},"modified":"2018-09-28T14:02:01","modified_gmt":"2018-09-28T18:02:01","slug":"ipo-boutique-comments-on-the-week-9-28-18","status":"publish","type":"post","link":"https:\/\/www.ipoboutique.com\/blog\/ipo-boutique-comments-on-the-week-9-28-18\/","title":{"rendered":"IPO Boutique Comments on The Week (9.28.18)"},"content":{"rendered":"<p><b>COMMENTARY REGARDING BIOTECH OFFERINGS THIS WEEK: <\/b><\/p>\n<p><span style=\"font-weight: 400;\">Entering the week, it seemed the IPO market had momentum and the quality of the deals (at least the U.S. ones) were quite good. But this week delivered quite a blow and leaves us thinking there could be \u201ccracks in the IPO market\u201d.<\/span><!--more--><\/p>\n<p><span style=\"font-weight: 400;\">It mainly revolves around the biotech debacle from this week.\u00a0<strong>Entasis Therapeutics (ETTX)<\/strong>, <strong>Urovant Sciences (UROV)<\/strong>, <strong>Sutro Biopharma (STRO)<\/strong> and <strong>Gritstone Oncology (GRTS)<\/strong> were either unmitigated disasters or came nowhere near their hype. The underwriters and\/or market makers are seemingly under the pretenses that they have no &#8220;duty&#8221; to assist broken issues. This is an expensive lesson for IPO investors who do not have information regarding IPOs leading up to their debuts.<\/span><\/p>\n<p>Entasis Pharmaceuticals and Urovant Sciences opened -10.3% and -25.0%, respectively!<\/p>\n<p><span style=\"font-weight: 400;\">The bio that opened strong, <strong>Arvinas Inc (ARVN)<\/strong>, traded under its issue price in the premarket of today\u2019s session! The Chinese IPO theme continues to be a wild card as they trade like its the wild, wild west.<\/span><\/p>\n<p>Is this a sign that the appetite for biotech offerings is waning? Was this to &#8220;scare away&#8221; fast money? <strong>These are the questions we are asking our sources and delivering to our paying client base.<\/strong><\/p>\n<p><span style=\"font-weight: 400;\"> The IPO market always has fast money. But with or without fast money&#8230;this week ended with a lot of soul searching and questions about what to expect with the large pipeline that is pending and ready for launch.\u00a0<\/span><\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>COMMENTARY REGARDING BIOTECH OFFERINGS THIS WEEK: Entering the week, it seemed the IPO market had momentum and the quality of the deals (at least the U.S. ones) were quite good. But this week delivered quite a blow and leaves us thinking there could be \u201ccracks in the IPO market\u201d.<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"zakra_general_container_width":0,"zakra_general_content_width":0,"zakra_general_sidebar_width":0,"zakra_sticky_header":"customizer","zakra_header_main_area":true,"zakra_site_logo_width":0,"zakra_header_top_enabled":"customizer","zakra_header_top_style":"customizer","zakra_primary_menu_item_style":"customizer","zakra_page_header_text_color":"","zakra_page_header_layout":"customizer","zakra_page_title_bg":"","zakra_footer_widgets_bg_image":0,"zakra_page_title_bg_repeat":"customizer","zakra_page_title_bg_position":"customizer","zakra_page_title_bg_size":"customizer","zakra_page_title_bg_attachment":"customizer","zakra_breadcrumbs_enabled":"customizer","zakra_breadcrumbs_text_color":"","zakra_breadcrumbs_separator_color":"","zakra_breadcrumbs_link_color":"","zakra_breadcrumbs_link_hover_color":"","zakra_page_title_bg_image":0,"zakra_footer_widgets_enabled":"customizer","zakra_footer_column_layout_1_style":"customizer","zakra_footer_widgets_bg":"","zakra_footer_widgets_bg_repeat":"customizer","zakra_footer_widgets_bg_position":"customizer","zakra_footer_widgets_bg_size":"customizer","zakra_footer_widgets_bg_attachment":"customizer","zakra_footer_bar_enabled":"customizer","zakra_footer_bar_style":"customizer","footnotes":""},"categories":[24],"tags":[],"class_list":["post-5409","post","type-post","status-publish","format-standard","hentry","category-ipo"],"_links":{"self":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/5409","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/comments?post=5409"}],"version-history":[{"count":2,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/5409\/revisions"}],"predecessor-version":[{"id":5411,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/5409\/revisions\/5411"}],"wp:attachment":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media?parent=5409"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/categories?post=5409"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/tags?post=5409"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}